Three medical marijuana companies are taking the Drug Enforcement Administration to federal court, arguing that the agency’s new restrictions on who they can buy from and sell to will shatter the state supply chains they depend on — and that the DEA imposed those restrictions without the authority to do so.
Lawyers for Standard Wellness Utah, Verde Americano in Arizona and NW Confections OK in Oklahoma filed a petition for review on Wednesday before the U.S. Court of Appeals for the District of Columbia Circuit. They are asking the court to rule on the agency’s actions — or to issue an administrative stay — before November 25, four days before the deadline takes effect.
The lawsuit is the sharpest escalation yet in a rescheduling rollout that state regulators say has been defined by confusion, short notice and silence from the federal agency in charge of it.
The Deadline at the Center of the Case
Last month, the DEA announced it had granted federal registration and protections to hundreds of medical marijuana businesses under the Trump administration’s federal rescheduling move. In the same breath, the agency issued new guidance — an October 30 directive titled “DEA Medical Marijuana Timely Applicant Information” — warning that cannabis companies have until November 29 to begin sourcing product only from and to other operators that have also been granted registration or applied for it in a timely fashion.
The distinction matters because state cannabis markets do not work the way the federal guidance assumes. States prohibit interstate commerce in marijuana, which means operators depend entirely on intrastate markets for manufacturing, distribution and dispensing. A business cannot simply replace a local supplier with one in another state. If the only suppliers in its state did not apply for DEA registration in time, it has nowhere else to go.
“This perfunctorily issued deadline ignores the realities of state markets, which prohibit interstate commerce — meaning that operators are entirely dependent on intrastate markets for manufacture, distribution, and dispensing,” the filing says. “By prohibiting ‘timely’ applicants from transacting with ‘non-timely’ applicants, the deadline overlooks that a given state may not have enough timely operators to satisfy its needs.”
The companies say the market has already reacted. Utah pharmacies and processors are refusing to deal with non-timely applicants, and one is quarantining about $80,000 of Standard Wellness Utah product delivered the day before it refused further purchases. Two major Verde customers have demanded proof of its DEA status, and a large multi-location customer has paused its orders. NW Confections has identified 15 non-timely dispensary customers, operating about 23 locations, that it will stop serving after November 29.
The Human Cost, in the Companies’ Own Numbers
The petition puts hard numbers on what the deadline would cost. After November 29, Standard Wellness Utah says it will lose monthly sales averaging about $275,900, along with the suppliers of about 16 percent of its oil. NW Confections expects its Oklahoma business to become insolvent. Verde expects to reduce its workforce by 70 percent.
“By bifurcating state medical marijuana marketplaces as of a date certain, DEA has disrupted settled expectations,” the filing argues. “On November 29, the Information will sever the supply relationships on which each Petitioner depends, and nothing this Court does later can restore the customers, suppliers, shelf space, employees, and licenses lost.”
The companies say they directly asked the DEA to suspend the November deadline. The agency has not replied.
Three Legal Arguments
The petition argues the October 30 directive is unlawful for three reasons.
First, it says the directive contradicts the rescheduling order that Attorney General Todd Blanche issued in April, and exceeds the agency’s authority. That final order promised that early applicants “may lawfully operate under their state-issued licenses during the pendency of review,” and the regulation authorizes timely applicants to operate in conformity with a state-issued license while an application is pending. Neither document sets a calendar end date, and neither conditions that authority on the status of an applicant’s trading partners. Yet the new guidance requires timely applicants to verify the status of their trading partners and restructure their supply chains by November 29, 2026.
Second, the companies argue the directive amounts to a legislative rule that was improperly issued without notice and comment. “The requirement that timely applicants verify their trading partners’ status and restructure their supply chains, on pain of denial or revocation, exists nowhere but in the Information,” the petition says — meaning the obligation was created by a guidance letter, not through the rulemaking process federal law requires.
Third, the petition calls the move arbitrary and capricious, because the DEA failed to consider the reliance interests it discarded. “DEA recognized that timely applicants would need to ‘make necessary adjustments to their supply chain,’ then gave them 30 days,” the filing says. “The Information never asks what severing existing trading relationships on 30 days’ notice would cost, who would bear it, or whether it is justified. Those costs fall on both sides of every severed relationship: on timely applicants that lose their trading partners, and on non-timely licensees that lose their customers and suppliers.”
The States the DEA Has Already Shut Out
The lawsuit lands alongside a second, quieter crisis in the same rollout. The DEA has been refusing to grant federal registration and protections to medical marijuana businesses in at least six states and Washington, D.C., sending orders to show cause to applicants in California, Delaware, the District of Columbia, Illinois, Minnesota, North Dakota and Oregon.
The orders cite provisions of those states’ laws as reasons the agency cannot register any business within those jurisdictions. The DEA generally points to states allowing businesses to sell non-medical marijuana as a violation of the Controlled Substances Act’s “closed system” for medical access and of U.S. international treaty obligations. Some documents also single out state laws that allow certain patients to access medical cannabis without a doctor’s written recommendation.
State cannabis regulators have expressed frustration with the agency’s actions and its general refusal to communicate about its plans. Gillian Schauer of the Cannabis Regulators Association, who represents state officials across the country, wrote recently that the way the DEA is implementing rescheduling has “created deep uncertainty and disruption for regulators, patients and market operators” — and came with “little or no advance notice to state regulators and minimal communication afterward.”
“Supply chains in many states will not have enough cultivators, manufacturers and dispensaries to support a viable supply chain in either the DEA market or the state-only market,” Schauer wrote. “With bifurcated and incomplete supply chains in states, some businesses will not survive in either market, patient access will be impacted, diversion and inversion will become more difficult for regulators to detect, health and safety compliance will be eroded and state revenues that support a variety of public services will decrease.”
How We Got Here
The current fight traces back to April 2026, when the Attorney General issued a final order moving state-licensed medical marijuana and FDA-approved marijuana products from Schedule I to Schedule III of the Controlled Substances Act, effective April 28. The order created a federal registration route for qualifying state-licensed operators and lifted the Internal Revenue Code Section 280E deduction disallowance for covered medical activities. Adult-use cannabis remains in Schedule I, outside both the registration pathway and the tax relief.
On October 30, the DEA issued the first federal registrations to state-licensed medical cannabis dispensaries — the Justice Department reported more than 900 approvals across seven medical-only states — and simultaneously set the November 29 deadline for every medical cannabis business to confirm it buys from and sells to only DEA registrants or timely applicants. Operators that miss the deadline, or keep dealing with businesses outside the federal system, risk denial of their pending applications or revocation of their registrations.
A separate DEA hearing on whether marijuana generally should move to Schedule III has produced no decision and no timeline — so the framework now in dispute applies only to state-licensed medical cannabis and FDA-approved products.
Congress, meanwhile, is circling the same questions. A Senate Appropriations Committee proposal released in November would extend the long-standing federal protection for state medical marijuana programs through the fiscal 2027 spending bill — a draft measure, not enacted law — while declining to adopt House language that would block federal officials from carrying out rescheduling. The backdrop is a rescheduling process that has moved faster in press releases than in practice.
What Happens Next
The companies want the D.C. Circuit to act before November 25, arguing that once the deadline severs their supply relationships, no later court ruling can restore what is lost: customers, suppliers, shelf space, employees and licenses. Whether the court grants a stay that quickly remains to be seen, but the filing makes one thing clear: for the businesses caught between state law and federal guidance, the rescheduling rollout is no longer a policy debate. It is an existential deadline, four days after Thanksgiving, with the clock already running.
The post Medical Marijuana Companies Sue the DEA Over a November 29 Deadline They Say Will Break Their Supply Chains appeared first on The Hype Magazine.

6 hours ago
2
